2005.03

Establishment (Gunpo, Gyeonggi)

2008.02

Relocate H.Q (Suwon, Gyeonggi)

2009.09

Established R&D Institute

2012.06

Patented SA-001 oral administrative drug for Xerophthalmia,
Contract for the transfer of technology with Samjin Pharmaceutical Co., Ltd. (SA-001)
Phase II study is on progress.

2019.05

Development of Uvimax DHHB & Uvimax TDSA UV blocking active ingredient

2019.11

Started to Pilot the Uvimax DHHB

2020.02

Started to product the Uvimax DHHB

2021.12

Completed building Janghang Factory (Janghang, Seocheon)

2022.09

Acquired EFfCI GMP Certification

2022.09

Acquired ISO 9001